LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
|
NEW YORK, Nov. 6, 2020 /PRNewswire/ -- The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, is proud to announce important results of 21 studies supported by the LRA to be presented at ACR Convergence 2020 – this year's virtual annual meeting of the American College of Rheumatology.
Studies will represent the LRA's breadth of research encompassing the full continuum of science from fundamental research through clinical trials. Basic research findings will cover the impact of lupus on a variety of immune cells throughout the body. Clinical research conducted through LRA's affiliate Lupus Therapeutics and its Lupus Clinical Investigators Network (LuCIN) include results for three studies including one for the investigational therapy iberdomide being tested for lupus in collaboration with Bristol Myers Squibb (BMS). In addition, furthering understanding of lupus nephritis and its treatment are 10 presentations by the AMP RA/SLE program, a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several other nonprofit groups and managed by the Foundation for the NIH (FNIH). "While online due to COVID-19 circumstances, ACR Convergence 2020 continues to advance lupus research by gathering the lupus scientific community to share their work with thousands of colleagues from around the world," said LRA President and CEO Kenneth M. Farber. "The LRA is proud to see many of the studies we funded deliver discoveries that will further treatment advances. And we particularly look forward to new data being presented on the effectiveness and safety of belimumab for treating lupus nephritis, the most common complication of lupus." Fundamental Research Funded by the LRA LRA-funded researchers will be presenting their work uncovering lupus' impact on a wide variety of immune cells. Several presentations will focus on changes in kidney immune cells during lupus nephritis. Other studies examine the impact of epigenetics, the microbiome and extracellular DNA during disease progression. Demographic and medical factors impacting patient participation in clinical trials will also be reported. Oral Presentations: The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion Epigenetic regulation of AID and the autoantibody response by the histone deacetylase Sirt1 Opposing T cell Responses in Autoimmunity Immune Cells Across Individual Pediatric Lupus Patients Molecular and Cellular Mechanisms of Autoimmunity to Extracellular DNA Poster Presentations: Single-Cell Transcriptomics of Mouse and Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis Clinical Trials Conducted by Lupus Therapeutics Several of the first studies conducted by Lupus Therapeutics, the clinical trial affiliate of LRA and its LuCIN network include its first clinical trials of potential new drug treatments for lupus. Oral Presentation: Poster Presentations: Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus Studies by Accelerating Medicines Partnership Ten studies arising from the AMP RA/SLE will be presented at ACR. Many of the studies focus on ways to diagnose, monitor, and treat lupus nephritis – kidney inflammation. Plenary Session II: AMP SLE Plenary: ET Single Cell Transcriptomic Analyses of Lupus Nephritis Kidney Urine Proteomics in Lupus Nephritis: Implications for a Liquid Biopsy What Have We Learned About SLE from AMP, and Where Are We Going? Oral Presentations: The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership Poster Presentations: Lupus Nephritis and Renal Outcomes in African Americans: The Accelerating Medicines Partnership Cohort Experience Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership Other Key Clinical Studies in Lupus News from ACR Convergence 2020 includes results of many trials looking at several potential new lupus treatments. Of the brief sampling below, most notable is new data from two large Phase 3 studies testing the existing drug belimumab (Benlysta®) for possible use in lupus nephritis. Plenary and Oral Presentations: BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis Poster Presentations: Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials The research presented at ACR Convergence 2020 highlights the full range of research funded each year by the LRA. Basic research studies uncovered changes in immune cells associated with lupus flares and lupus nephritis. Several clinical trials show promising results, including a trial using belimumab to treat lupus nephritis and a trial using iberdomide to treat active lupus. About Lupus About the Lupus Research Alliance About Lupus Therapeutics *All presentation times are Eastern Standard Time
SOURCE Lupus Research Alliance |
View original content to download multimedia: